Innovation is at the heart of our product portfolio

Oncology candidates

Pipeline is available for partnering opportunities (other than MOR209/ES414)
Otlertuzumab, originally known as TRU-016 (anti-CD37)
Pre-clinical Phase 1 Phase 2 Phase 3
MOR209/ES414 (anti-PSMA x anti-CD3)
Pre-clinical Phase 1 Phase 2 Phase 3
APVO425 (anti-ROR1 x anti-CD3)
Pre-clinical Phase 1 Phase 2 Phase 3
Additional RTCC assets (targets not disclosed)
Pre-clinical Phase 1 Phase 2 Phase 3

Autoimmune, inflammation and infectious disease/other candidates

Name
Pre-clinical
Phase 1
Phase 2
Phase 3
 
 
 
 
 
 
ES210 (anti-CD86 x monoIL-10)
Pre-clinical Phase 1 Phase 2 Phase 3
Alzheimer’s
Pre-clinical Phase 1 Phase 2 Phase 3
Other Candidates
Pre-clinical Phase 1 Phase 2 Phase 3